Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers (Q38867798)

7 September 2017

Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers (English)

1 reference

7 September 2017

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Xinying Li

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Yanting Duan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Chunxia Qiao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Tingting Zhou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ming Yu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jiannan Feng

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Beifen Shen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ming Lv

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Yan Li

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

3 June 2015

1 reference

Technology in Cancer Research and Treatment

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

573-582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Anti-HER2 vaccines: new prospects for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

The promise of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Activity and resistance of trastuzumab according to different clinical settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

IGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Mechanisms of resistance to HER family targeting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Resistance to EGFR-targeted therapy: a family affair

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

The promise of anti-ErbB3 monoclonals as new cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

De novo design TNF-alpha antagonistic peptide based on the complex structure of TNF-alpha with its neutralizing monoclonal antibody Z12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533034615588422

21 January 2018

Identifiers

DOI

10.1177/1533034615588422

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041400%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference